Skip to main content

Table 4 Change in observed and predicted utility scores

From: Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis

   Observed Predicted Difference
(Observed-Predicted)
Study, follow-up n Mean
(SD)
Mean
(SD)
R 2 Mean
(95% CI)
95% reference range
EQ-5D       
STIVEA,
1-year
159 0.20
(0.31)
0.12 (0.24) 0.22 -0.07
(-0.12, -0.03)
-0.50 to 0.64
BROSG,
3-year
375 -0.06
(0.24)
-0.06 (0.24) 0.08 -0.00
(-0.02, 0.02)
-0.50 to 0.50
BSRBR,
6-month
749 0.08
(0.33)
0.07 (0.25) 0.19 -0.01
(-0.04, 0.01)
-0.60 to 0.63
SF-6D       
STIVEA,
1-year
159 0.13
(0.16)
0.04 (0.07) 0.46 -0.09
(-0.11, -0.07)
-0.14 to 0.33
BROSG,
3-year
375 -0.02
(0.11)
-0.02 (0.05) 0.11 -0.00
(-0.01, 0.01)
-0.21 to 0.21
BSRBR,
6-month
749 0.05
(0.12)
0.02 (0.06) 0.33 -0.03
(-0.03, -0.02)
-0.16 to 0.21
  1. Abbreviations: BROSG = British Rheumatoid Outcome Study Group, BSRBR = British Society for Rheumatology Biologics Register, EQ-5D = EuroQol-5D, SF-6D = Short Form-6D, STIVEA = Steroids In Very Early Arthritis